DGAP-News: Biotest AG: Biotest exceeds sales guidance in fiscal year 2021
In fiscal year 2021, the Biotest Group generated revenues of 515.6 million, compared to 484.2 million in the previous year.
- In fiscal year 2021, the Biotest Group generated revenues of 515.6 million, compared to 484.2 million in the previous year.
- This result is a consequence of growth in key sales markets due to the positive sales development of the main product Intratect(R).
- EBIT amounted to - 47.1 million in fiscal 2021, compared to - 1.3 million in the previous year.
- The Biotest Group's loss (EAT) for the financial year 2021 was - 63.4 million, compared to - 31.4 million in 2020.